White label – Pompe disease - ClinicalTrials.eu

Study of Lisaftoclax combined with azacitidine for elderly patients with newly diagnosed acute myeloid leukemia

Recruiting

3 1 1
Investigated Drugs:
- Lisaftoclax
- Azacitidine
Study of levetiracetam to prevent seizures in adults who have both Down syndrome and Alzheimer’s disease

Recruiting

3 1 1
Investigated Diseases:
- Trisomy 21
- Dementia Alzheimer’s type
Investigated Drugs:
- Levetiracetam
Study of TAK-360 tablets to evaluate safety and effectiveness in people with Idiopathic Hypersomnia

Recruiting

2 1
Study on the Effectiveness and Safety of Mannan-Conjugated Allergoids for Treating Allergic Rhinitis/Rhinoconjunctivitis in Patients Allergic to House Dust Mites

Recruiting

3 1
Investigated Diseases:
Study on the Effectiveness and Safety of Mannan-Conjugated Allergoids for Treating Allergic Rhinitis/Rhinoconjunctivitis in Patients Allergic to House Dust Mites

Recruiting

3 1
Study on the Effectiveness and Safety of Zasocitinib (TAK-279) for Patients with Active Psoriatic Arthritis with Previous Biologic Treatment

Recruiting

3 1
Investigated Diseases:
- Psoriatic arthropathy
Investigated Drugs:
- Zasocitinib
Study of Pembrolizumab with Cisplatin or Carboplatin and Etoposide for Patients with Advanced Merkel Cell Carcinoma

Recruiting

2 1 1 1
Investigated Drugs:
Study Comparing Ipilimumab and Nivolumab to Nivolumab Alone for Patients with Resectable Stage III Melanoma

Recruiting

3 1 1 1
Investigated Diseases:
- Malignant melanoma stage III
Investigated Drugs:
- Ipilimumab
- Nivolumab
Study on the Safety of CNTY-101 and Aldesleukin for Patients with Active Autoimmune Diseases: Lupus, Scleroderma, and Myositis

Recruiting

1 1 1 1
Investigated Diseases:
Investigated Drugs:
- Aldesleukin
Study on the Safety and Effectiveness of Emicizumab for Patients with Type 3 Von Willebrand Disease

Recruiting

3 1 1 1
Investigated Diseases:
- Von Willebrand’s disease
Investigated Drugs:
+2

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies